Expert Interviews
Expert Interviews
Advertisement
Ariana L. Smith, MDSUO 2023 | December 20, 2023
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Read More
Mark T. Fleming, MDProstate Cancer | October 18, 2023
Dr. Fleming details his early-phase clinical trial work that has had the largest impact on patients with GU malignancies.
Peter C. Black, MDNon-Muscle Invasive Urothelial Carcinoma | September 29, 2023
Dr. Black shares the basis for testing atezolizumab in BCG-unresponsive NMIBC as well as the implications of SWOG S1605.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Guru P. Sonpavde, MDMuscle Invasive Urothelial Carcinoma | August 31, 2023
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Arlene O. Siefker-Radtke, MDAdvanced Urothelial Carcinoma | July 12, 2023
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | August 23, 2023
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBAExpert Interviews | May 3, 2023
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
David Ambinder, MDProstate Cancer | April 1, 2023
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
Emily MenendezExpert Interviews | October 12, 2023
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
A. Ari Hakimi, MDAdvanced Renal Cell Carcinoma | April 7, 2023
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Preston Sprenkle, MDProstate Cancer | April 7, 2023
Dr. Sprenkle shares his inspiration to practice urologic oncology and his role in popularizing the Artemis Device.
Vignesh Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | March 24, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Sangeeta Goswami, MD, PhDUrothelial Carcinoma | February 5, 2024
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Akhil Abraham Saji, MDProstate Cancer | April 7, 2023
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | August 23, 2023
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Rachelle Rodriguez, MS, APRN, AOCNPExpert Interviews | April 7, 2023
Rachelle Rodriguez, MS, APRN, AOCNP, highlights her role in helping Moffitt grow its APP presence within the GU onc program.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | February 14, 2023
David Braun, MD, PhD, highlights the available later-line therapy options for RCC, how the therapies are sequenced, and more.
Rishabh Simhal, MDExpert Interviews | February 10, 2023
Rishabh Simhal, MD, discusses baseline fatigue and OS in patients with prostate cancer, as well as the FACIT-F questionnaire.
Yair Lotan, MDUpper Tract Urothelial Carcinoma | February 10, 2023
Yair Lotan, MD, details the real-world use, effectiveness, and standard-of-care potential of UGN-101 for patients with UTUC.
Advertisement
Advertisement
Advertisement